ROLE OF THE KNOWN MUCOLYTICS IN MUCOVISCIDOSIS THERAPY

Abstract

The primary objective in the mucoviscidosis therapy is to ensure normal rheology of respiratory secretion for effective evacuationthereof from the bronchial tree and nasal sinuses. Enzyme drug dornase alfa features the best evidence base for effectiveness and safety of use to treat mucoviscidosis among mucolytics; it rapidly transforms thick viscous sputum into liquid secretion. Along with that, numerous studies have confirmed anti-inflammatory and antibacterial effects thereof: the enzyme breaks down biofilm of the mucoid Pseudomonas aeruginosa, thus reducing volume of the destructive component in pulmonary tissue in the event of an inflammation; it is capable of decreasing concentration of neutrophil elastase and interleukin 8 in sputum, as well as of matrix metal proteinases in bronchoalveolar lavage. Continuous intake of this drug in combination with kinesitherapy and other baseline drugs ensures the patient’s well-being, lower rate of bronchopulmonary process exacerbations, reduction in the hospital admission rate and significant improvement of the quality of life.

Keywords

• mucoviscidosis
• chronic bronchitis
• treatment
• dornase alfa
• mucolytics
• children